In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G

This article was originally published in The Rose Sheet

Executive Summary

The Gillette Fusion shaving system generated retail sales of more than $220 mil. within the first seven months of its January launch, Procter & Gamble President and CEO A.G. Lafley states during the firm's annual shareholder meeting Oct. 10. P&G estimated the product would achieve $1 bil. in sales by its third year on shelves (1"The Rose Sheet" Sept. 19, 2005, p. 7). Additionally, the exec updated analysts on the firm's progress in integrating Gillette, which the personal care company acquired for $57 bil. in early 2005 (2"The Rose Sheet" Jan. 31, 2005, p. 3). Nearly 80% of Gillette and P&G commercial operations will be integrated by the end of October, 2006, Lafley notes. "We've managed all these integration details while delivering business and financial commitments on the established businesses," he adds...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel